Goldman Sachs upgraded Pro Medicus to Buy from Neutral with a price target of A$76, up from A$57.90. The firm expects the adoption of Pro Medicus’ technology to expand and its new estimates imply a 22% EBITDA compound annual growth rate from FY23-26.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PMCUF: